LianBio
NASDAQ:LIAN
Intrinsic Value
LianBio operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one LIAN stock under the Base Case scenario is 0.17 USD. Compared to the current market price of 0.29 USD, LianBio is Overvalued by 40%.
Valuation Backtest
LianBio
Run backtest to discover the historical profit from buying and selling LIAN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
LianBio
Current Assets | 257.8m |
Cash & Short-Term Investments | 252.3m |
Receivables | 1.8m |
Other Current Assets | 3.7m |
Non-Current Assets | 5.1m |
PP&E | 5m |
Other Non-Current Assets | 100k |
Current Liabilities | 25.6m |
Accounts Payable | 6.2m |
Accrued Liabilities | 17.8m |
Other Current Liabilities | 1.6m |
Non-Current Liabilities | 35m |
Other Non-Current Liabilities | 35m |
Earnings Waterfall
LianBio
Revenue
|
0
USD
|
Operating Expenses
|
-106.6m
USD
|
Operating Income
|
-106.6m
USD
|
Other Expenses
|
18.6m
USD
|
Net Income
|
-88m
USD
|
Free Cash Flow Analysis
LianBio
What is Free Cash Flow?
LIAN Profitability Score
Profitability Due Diligence
LianBio's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
LianBio's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
LIAN Solvency Score
Solvency Due Diligence
LianBio's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
LianBio's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LIAN Price Targets Summary
LianBio
According to Wall Street analysts, the average 1-year price target for LIAN is 3.98 USD with a low forecast of 3.03 USD and a high forecast of 5.04 USD.
Ownership
LIAN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LIAN Price
LianBio
Average Annual Return | -64.7% |
Standard Deviation of Annual Returns | 14.18% |
Max Drawdown | -100% |
Market Capitalization | 449.6m USD |
Shares Outstanding | 1 550 415 089 |
Percentage of Shares Shorted | 0.83% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
LianBio operates as a biopharmaceutical company. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2021-10-28. The firm has established production lines for nine candidate products, including Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX13, LYR210, Sisunatovir. The firm's products cover five different treatment areas, including cardiovascular, cancer, ophthalmology, inflammatory diseases and respiratory indications.
Contact
IPO
Employees
Officers
The intrinsic value of one LIAN stock under the Base Case scenario is 0.17 USD.
Compared to the current market price of 0.29 USD, LianBio is Overvalued by 40%.